filmov
tv
Understanding Higher Risk MDS and the Transition to AML
Показать описание
Presented by Dale Schaar, MD, PhD, dhis session will provide a comprehensive overview of high risk MDS and the transition to AML, from diagnosis to treatment.
AAMDSIF
Рекомендации по теме
1:13:29
Understanding Higher Risk MDS and Transtion to AML
1:11:26
Understanding Higher Risk MDS and the Transition to AML
0:33:29
Higher-risk MDS and AML: How new guidelines are changing diagnosis, classification and management
0:03:08
The treatment protocol for higher risk MDS
0:02:50
How is higher-risk MDS treated?
1:02:31
Understanding QoL (Quality of life) in High-Risk MDS & AML
0:01:25
Prognosis and treatment in high-risk MDS
1:16:58
What Are My Options with High Risk MDS AML
0:15:00
Top MPN highlights from ASH 2024 & trials to look out for in 2025: expert insights
0:01:17
How is higher-risk MDS-related anemia treated?
0:04:16
How are high risk and low risk MDS defined? #MDS
1:32:06
High Risk MDS Treatment Strategies
0:00:59
The current challenges facing high-risk MDS treatment
0:03:31
Promising treatment options emerging for higher-risk MDS & the value of clinical trials
0:01:21
Future treatment priorities for high-risk MDS
0:03:38
How serious a cancer is MDS? What is the prognosis for MDS?
0:07:26
Treatment Goals for Higher Risk MDS
0:14:08
Low-Risk and High-Risk MDS
0:57:07
Higher-risk MDS and newly diagnosed AML: What are the latest developments from EHA 2022?
0:01:26
Understanding High Risk Acute Myeloid Leukemia Treatment Advances and Options
0:55:44
Low Risk vs High Risk MDS - What's the Difference?
0:01:27
Exciting updates in higher-risk MDS at ASH 2022
0:02:13
Optimizing therapy for patients with high-risk MDS
0:22:08
A Unified Approach to Higher Risk MDS: Standard and Emerging Therapies